{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:37:43Z","timestamp":1792679863167,"version":"4.5.0"},"reference-count":148,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Bronchiectasis is a heterogeneous chronic airway disease primarily driven by persistent infection, microbial dysbiosis and dysregulated host immunity. While culture-based microbiology has historically informed clinical management, advances in high-throughput sequencing and multi-omic technologies have transformed our understanding of the airway ecosystem, revealing that disease activity is shaped not only by individual pathogens, but by complex and dynamic host\u2013microbe interactions. Despite the breadth of descriptive microbiome data, translation into clinically actionable diagnostics or therapies has been limited. Importantly, cross-sectional correlations between microbiota and inflammation do not establish cause and effect, underscoring the need to embed host\u2013microbiome profiling within both longitudinal and interventional therapeutic trials. In this review, we critically appraise current microbial and host multi-omics research in bronchiectasis, integrating microbiome studies with host inflammatory, proteomic and immunophenotyping data. We highlight themes emerging across cohorts, including low microbial diversity, pathogen dominance, loss of commensal networks and neutrophil-driven inflammation, and discuss how these features align with biological endotypes associated with exacerbations and treatment response. Drawing on lessons from host-directed therapeutic successes, we examine translational roadblocks limiting microbiome-guided care. We further review emerging microbiome-modulating strategies such as pathogen-specific biologics, bacteriophage therapy, live biotherapeutic products, biofilm-targeting adjuncts and precision antibiotic stewardship. Finally, we propose a roadmap toward microbiome-informed precision medicine through harmonised methodologies, integration of host and microbial biomarkers into clinical trials, and embedding multi-omics pipelines within large international registries. Collectively, these advances have the potential to shift bronchiectasis research and clinical management towards rationally designed, precision medicine-driven therapeutic strategies.<\/jats:p>","DOI":"10.1183\/13993003.00239-2026","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:05:21Z","timestamp":1781193921000},"page":"2600239","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies"],"prefix":"10.1183","volume":"68","author":[{"given":"Christina S.","family":"Thornton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schaupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Tunney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026102206401530000_68.3.2600239.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202819"},{"key":"2026102206401530000_68.3.2600239.2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jama.2025.2680","article-title":"Non-cystic fibrosis bronchiectasis in adults: a review","volume":"334","author":"Barker","year":"2025","journal-title":"JAMA"},{"key":"2026102206401530000_68.3.2600239.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01126-2025"},{"key":"2026102206401530000_68.3.2600239.4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0015-2023"},{"key":"2026102206401530000_68.3.2600239.6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026102206401530000_68.3.2600239.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202403-0473PP"},{"key":"2026102206401530000_68.3.2600239.8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2019"},{"key":"2026102206401530000_68.3.2600239.9","first-page":"6","article-title":"Inflammation: a two-edged sword \u2013 the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl"},{"key":"2026102206401530000_68.3.2600239.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01050-2024"},{"key":"2026102206401530000_68.3.2600239.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2023.03.004"},{"key":"2026102206401530000_68.3.2600239.12","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2024"},{"key":"2026102206401530000_68.3.2600239.13","first-page":"4101","article-title":"Endotyping bronchiectasis through multi-omic profiling","volume":"56","author":"Keir","year":"2026","journal-title":"Eur Respir J"},{"key":"2026102206401530000_68.3.2600239.14","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0234-2023"},{"key":"2026102206401530000_68.3.2600239.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021713"},{"key":"2026102206401530000_68.3.2600239.16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102206401530000_68.3.2600239.17","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00633-2022"},{"key":"2026102206401530000_68.3.2600239.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01551-2024"},{"key":"2026102206401530000_68.3.2600239.19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-2600(25)00019-0","article-title":"Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"13","author":"Zhong","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-2600(20)30557-9","article-title":"The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study","volume":"9","author":"Dicker","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.21","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01131-2024"},{"key":"2026102206401530000_68.3.2600239.22","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0038-2024"},{"key":"2026102206401530000_68.3.2600239.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01289-7"},{"key":"2026102206401530000_68.3.2600239.24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12931-025-03140-w","article-title":"Pulmonary microbiology and microbiota in adults with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis","volume":"26","author":"Wang","year":"2025","journal-title":"Respir Res"},{"key":"2026102206401530000_68.3.2600239.25","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01008-2023"},{"key":"2026102206401530000_68.3.2600239.26","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0048-2019"},{"key":"2026102206401530000_68.3.2600239.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42862-y"},{"key":"2026102206401530000_68.3.2600239.28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1164\/rccm.202402-0352ED","article-title":"Vive la resistome: are we ready for a metagenomics revolution in bronchiectasis?","volume":"210","author":"Singh","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1059OC"},{"key":"2026102206401530000_68.3.2600239.30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00054-2025"},{"key":"2026102206401530000_68.3.2600239.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170622"},{"key":"2026102206401530000_68.3.2600239.32","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.chom.2022.08.012","article-title":"A lung pathobiont story: thinking outside the Koch's postulate box","volume":"30","author":"Singh","year":"2022","journal-title":"Cell Host Microbe"},{"key":"2026102206401530000_68.3.2600239.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.08.005"},{"key":"2026102206401530000_68.3.2600239.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.3843"},{"key":"2026102206401530000_68.3.2600239.35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1176044"},{"key":"2026102206401530000_68.3.2600239.36","doi-asserted-by":"crossref","first-page":"100206","DOI":"10.1016\/j.bioflm.2024.100206","article-title":"Antibiofilm activity of Prevotella species from the cystic fibrosis lung microbiota against Pseudomonas aeruginosa","volume":"7","author":"Grassi","year":"2024","journal-title":"Biofilm"},{"key":"2026102206401530000_68.3.2600239.37","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0179-2024"},{"key":"2026102206401530000_68.3.2600239.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01966-2023"},{"key":"2026102206401530000_68.3.2600239.39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202310-1729OC"},{"key":"2026102206401530000_68.3.2600239.40","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1164\/rccm.202303-0499OC","article-title":"Inflammatory molecular endotypes in bronchiectasis: a European multicenter cohort study","volume":"208","author":"Choi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.chest.2025.07.4087","article-title":"Inflammatory and mucociliary dysfunction-based endotypes across the spectrum of chronic airway diseases","volume":"168","author":"Cant","year":"2025","journal-title":"Chest"},{"key":"2026102206401530000_68.3.2600239.43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4046\/trd.2024.0078","article-title":"Increased neutrophil elastase in affected lobes of bronchiectasis and correlation of its levels between sputum and bronchial lavage fluid","volume":"88","author":"Nguyen-Ho","year":"2025","journal-title":"Tuberc Respir Dis"},{"key":"2026102206401530000_68.3.2600239.44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.arbres.2025.10.012","article-title":"Systemic immune dysregulation in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"62","author":"Solarat","year":"2026","journal-title":"Arch Bronconeumol"},{"key":"2026102206401530000_68.3.2600239.45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00150-2025"},{"key":"2026102206401530000_68.3.2600239.46","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1016\/j.csbj.2023.10.016","article-title":"The application of multi-omics in the respiratory microbiome: progresses, challenges and promises","volume":"21","author":"Gao","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"2026102206401530000_68.3.2600239.47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.OA1456"},{"key":"2026102206401530000_68.3.2600239.48","doi-asserted-by":"crossref","first-page":"100220","DOI":"10.1016\/j.endmts.2025.100220","article-title":"Metabolomics identify serum biomarkers for predicting acute exacerbation and severity of bronchiectasis","volume":"17","author":"Yan","year":"2025","journal-title":"Endocr Metab Sci"},{"key":"2026102206401530000_68.3.2600239.49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12890-025-03904-6","article-title":"Bronchoalveolar lavage proteomics in exacerbation of bronchiectasis","volume":"25","author":"Lee","year":"2025","journal-title":"BMC Pulm Med"},{"key":"2026102206401530000_68.3.2600239.50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2024.OA2791"},{"key":"2026102206401530000_68.3.2600239.51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.arbres.2025.01.002","article-title":"Sputum microbiota correlates with metabolome and clinical outcomes in asthma\u2013bronchiectasis overlap","volume":"61","author":"Zhang","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"2026102206401530000_68.3.2600239.52","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1164\/rccm.202504-0875OC","article-title":"Upper airway microbiome, mucociliary function, and clinical outcomes in bronchiectasis: data from the EMBARC-BRIDGE study","volume":"211","author":"Choi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.06.010"},{"key":"2026102206401530000_68.3.2600239.54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4168\/aair.2026.18.1.19","article-title":"Precision medicine for asthma: tailored to its severity and endotype\/phenotype","volume":"18","author":"Chan","year":"2026","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026102206401530000_68.3.2600239.55","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0022-2018"},{"key":"2026102206401530000_68.3.2600239.56","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-025-03356-w"},{"key":"2026102206401530000_68.3.2600239.57","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00081-2025"},{"key":"2026102206401530000_68.3.2600239.58","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","article-title":"Rethinking bronchiectasis as an inflammatory disease","volume":"12","author":"Long","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.59","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201501-029OC"},{"key":"2026102206401530000_68.3.2600239.60","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2019-0273TR"},{"key":"2026102206401530000_68.3.2600239.61","doi-asserted-by":"crossref","unstructured":"Dickson RP . Approaches to sampling the respiratory microbiome. In: Huang YJ , Garantziotis S , eds. The Microbiome in Respiratory Disease: Principles, Tools and Applications. Cham, Springer International Publishing, 2022; pp. 3\u201319. Doi: 10.1007\/978-3-030-87104-8_1","DOI":"10.1007\/978-3-030-87104-8_1"},{"key":"2026102206401530000_68.3.2600239.62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40793-022-00425-1","article-title":"Metadata harmonization-standards are the key for a better usage of omics data for integrative microbiome analysis","volume":"17","author":"Cernava","year":"2022","journal-title":"Environ Microbiome"},{"key":"2026102206401530000_68.3.2600239.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026102206401530000_68.3.2600239.64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12\u2005years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01783-2025"},{"key":"2026102206401530000_68.3.2600239.66","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219943"},{"key":"2026102206401530000_68.3.2600239.67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI184171"},{"key":"2026102206401530000_68.3.2600239.68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00616-2025"},{"key":"2026102206401530000_68.3.2600239.69","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2026102206401530000_68.3.2600239.70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022"},{"key":"2026102206401530000_68.3.2600239.71","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2023"},{"key":"2026102206401530000_68.3.2600239.72","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1943so"},{"key":"2026102206401530000_68.3.2600239.73","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026102206401530000_68.3.2600239.74","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"2026102206401530000_68.3.2600239.75","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1164\/rccm.202408-1545OC","article-title":"Broad immunomodulatory effects of the dipeptidyl peptidase-1 inhibitor brensocatib in bronchiectasis: data from the phase 2, double-blind, placebo-controlled WILLOW trial","volume":"211","author":"Johnson","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.76","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur Respir J"},{"key":"2026102206401530000_68.3.2600239.77","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2290"},{"key":"2026102206401530000_68.3.2600239.78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.79","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1164\/rccm.202501-0159OC","article-title":"Endotypes of Pseudomonas aeruginosa infection in bronchiectasis are associated with inhaled antibiotic response: results from two randomized, double-blind, placebo-controlled phase III trials (ORBIT 3 and ORBIT 4)","volume":"211","author":"Hull","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.80","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S2213-2600(25)00160-2","article-title":"Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study","volume":"13","author":"Sibila","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.01.008"},{"key":"2026102206401530000_68.3.2600239.82","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02443-2024"},{"key":"2026102206401530000_68.3.2600239.83","doi-asserted-by":"crossref","first-page":"115662","DOI":"10.1016\/j.addr.2025.115662","article-title":"Towards airway microbiome engineering for improving respiratory health","volume":"225","author":"Hern","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"key":"2026102206401530000_68.3.2600239.84","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02086-2016"},{"key":"2026102206401530000_68.3.2600239.85","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/antibiotics11040474","article-title":"Microbiome modulation as a novel strategy to treat and prevent respiratory infections","volume":"11","author":"Mindt","year":"2022","journal-title":"Antibiotics"},{"key":"2026102206401530000_68.3.2600239.86","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202112-2704PP"},{"key":"2026102206401530000_68.3.2600239.87","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00821-x"},{"key":"2026102206401530000_68.3.2600239.88","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/pathogens14040355","article-title":"From microbial ecology to clinical challenges: the respiratory microbiome's role in antibiotic resistance","volume":"14","author":"Niculescu","year":"2025","journal-title":"Pathogens"},{"key":"2026102206401530000_68.3.2600239.89","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0121-2022"},{"key":"2026102206401530000_68.3.2600239.90","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MCP.0000000000001050","article-title":"Bacteriophages for bronchiectasis: treatment of the future?","volume":"30","author":"Dominic","year":"2024","journal-title":"Curr Opin Pulm Med"},{"key":"2026102206401530000_68.3.2600239.91","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac453"},{"key":"2026102206401530000_68.3.2600239.92","unstructured":"Armata Pharmaceuticals . Armata Pharmaceuticals Announces Encouraging Results From the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (Press Release). PR Newswire. 2024. www.prnewswire.com\/news-releases\/armata-pharmaceuticals-announces-encouraging-results-from-the-phase-2-tailwind-study-of-inhaled-ap-pa02-in-non-cystic-fibrosis-bronchiectasis-subjects-with-chronic-pulmonary-pseudomonas-aeruginosa-infection-302335676.html"},{"key":"2026102206401530000_68.3.2600239.93","unstructured":"BiomX . BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review (Press Release). 2025. https:\/\/ir.biomx.com\/news-releases\/news-release-details\/biomx-announces-discontinuation-phase-2b-bx004-trial-following"},{"key":"2026102206401530000_68.3.2600239.94","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01056-1"},{"key":"2026102206401530000_68.3.2600239.95","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217993109"},{"key":"2026102206401530000_68.3.2600239.96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41522-021-00234-3","article-title":"The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis","volume":"7","author":"Morris","year":"2021","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2026102206401530000_68.3.2600239.97","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00138-18"},{"issue":"Suppl. 1","key":"2026102206401530000_68.3.2600239.98","doi-asserted-by":"crossref","first-page":"A3117","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3117","article-title":"A bispecific monoclonal antibody targeting Psl and PcrV for chronic Pseudomonas aeruginosa infection in patients with bronchiectasis: results from a randomized, double-blind placebo-controlled trial (GREAT-2)","volume":"211","author":"Long","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.99","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2025.OA2312"},{"key":"2026102206401530000_68.3.2600239.100","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1038\/s41598-022-09865-8","article-title":"Chimeric bacteriocin S5-PmnH engineered by domain swapping efficiently controls Pseudomonas aeruginosa infection in murine keratitis and lung models","volume":"12","author":"Pa\u0161kevi\u010dius","year":"2022","journal-title":"Sci Rep"},{"key":"2026102206401530000_68.3.2600239.101","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/ajrccm\/aamag135","article-title":"Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial","volume":"212","author":"Downey","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.102","unstructured":"ClinicalTrials.gov . Dose range finding, efficacy, and safety study of nebulized csl787 in adults with non-cystic fibrosis bronchiectasis (NCT07048262) [clinical trial registry entry]. 2025. https:\/\/clinicaltrials.gov\/study\/NCT07048262"},{"key":"2026102206401530000_68.3.2600239.103","doi-asserted-by":"crossref","first-page":"101371","DOI":"10.1016\/j.xcrm.2023.101371","article-title":"Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies","volume":"5","author":"Cauwenberghs","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026102206401530000_68.3.2600239.104","doi-asserted-by":"crossref","first-page":"115663","DOI":"10.1016\/j.addr.2025.115663","article-title":"Bioinspired approaches to encapsulate and deliver bacterial live biotherapeutic products","volume":"225","author":"Brittain","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"key":"2026102206401530000_68.3.2600239.105","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1038\/s41467-024-51169-0","article-title":"A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation","volume":"15","author":"Nicola","year":"2024","journal-title":"Nat Commun"},{"key":"2026102206401530000_68.3.2600239.106","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41587-022-01584-9","article-title":"Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms","volume":"41","author":"Mazzolini","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026102206401530000_68.3.2600239.107","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00086-2026"},{"key":"2026102206401530000_68.3.2600239.108","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2012.17"},{"key":"2026102206401530000_68.3.2600239.109","doi-asserted-by":"publisher","DOI":"10.1038\/nm1028"},{"key":"2026102206401530000_68.3.2600239.110","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200708-1233OC"},{"key":"2026102206401530000_68.3.2600239.111","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.5.1329"},{"key":"2026102206401530000_68.3.2600239.112","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jcf.2022.04.008","article-title":"Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis","volume":"21","author":"Markovetz","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026102206401530000_68.3.2600239.113","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210134"},{"key":"2026102206401530000_68.3.2600239.114","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.201906-1219OC","article-title":"Airway mucus hyperconcentration in non-cystic fibrosis bronchiectasis","volume":"201","author":"Ramsey","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.115","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0241-2021"},{"key":"2026102206401530000_68.3.2600239.116","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.05.006"},{"key":"2026102206401530000_68.3.2600239.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.07.019"},{"key":"2026102206401530000_68.3.2600239.118","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jamp.2017.1443","article-title":"Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial","volume":"31","author":"Herrero-Cortina","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026102206401530000_68.3.2600239.119","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.12.021"},{"key":"2026102206401530000_68.3.2600239.120","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa2510095","article-title":"Hypertonic saline or carbocisteine in bronchiectasis","volume":"393","author":"Bradley","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102206401530000_68.3.2600239.121","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02022-2022"},{"issue":"Suppl. 1","key":"2026102206401530000_68.3.2600239.122","doi-asserted-by":"crossref","first-page":"A4050","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A4050","article-title":"Safety and tolerability of a novel inhaled thiol-saccharide mucolytic (Fexlamose, MUC-031) in healthy volunteers","volume":"211","author":"Low","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.123","unstructured":"ClinicalTrials.gov . Study to evaluate the efficacy, safety, and tolerability of fexlamose in participants with chronic bronchitis\/COPD (NCT06731959) [Clinical trial registry entry]. U.S. National Library of Medicine 2026. https:\/\/clinicaltrials.gov\/study\/NCT06731959"},{"key":"2026102206401530000_68.3.2600239.124","doi-asserted-by":"crossref","unstructured":"Choi H , McShane PJ , Aliberti S , et al. Bronchiectasis management in adults: state of the art and future directions. Eur Respir J 2024; 63. doi:10.1183\/13993003.00518-2024","DOI":"10.1183\/13993003.00518-2024"},{"key":"2026102206401530000_68.3.2600239.125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-023-02562-8","article-title":"Differential airway resistome and its correlations with clinical characteristics in Haemophilus- or Pseudomonas-predominant microbial subtypes of bronchiectasis","volume":"24","author":"Yi","year":"2023","journal-title":"Respir Res"},{"key":"2026102206401530000_68.3.2600239.126","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piac040"},{"key":"2026102206401530000_68.3.2600239.127","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat Med"},{"key":"2026102206401530000_68.3.2600239.128","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1038\/s41467-025-60598-4","article-title":"Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial","volume":"16","author":"Weiner","year":"2025","journal-title":"Nat Commun"},{"key":"2026102206401530000_68.3.2600239.129","doi-asserted-by":"crossref","first-page":"106730","DOI":"10.1016\/j.micpath.2024.106730","article-title":"Beyond antibiotics: emerging antivirulence strategies to combat Pseudomonas aeruginosa in cystic fibrosis","volume":"193","author":"Mudgil","year":"2024","journal-title":"Microb Pathog"},{"key":"2026102206401530000_68.3.2600239.130","doi-asserted-by":"crossref","first-page":"108396","DOI":"10.1016\/j.rmed.2025.108396","article-title":"Anti-inflammatory agents for the management of COPD \u2013 Quo Vadis?","volume":"248","author":"Bakakos","year":"2025","journal-title":"Respir Med"},{"key":"2026102206401530000_68.3.2600239.131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00408-025-00844-0","article-title":"Emerging therapeutics in COPD: mapping innovation to treatable traits","volume":"203","author":"Cazzola","year":"2025","journal-title":"Lung"},{"key":"2026102206401530000_68.3.2600239.132","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00182-2026"},{"key":"2026102206401530000_68.3.2600239.133","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1615\/CritRevImmunol.2016015865","article-title":"Interleukin-33 and its receptor in pulmonary inflammatory diseases","volume":"35","author":"Zhao","year":"2015","journal-title":"Crit Rev Immunol"},{"key":"2026102206401530000_68.3.2600239.134","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.3390\/cimb46070398","article-title":"Potential new inflammatory markers in bronchiectasis: a literature review","volume":"46","author":"Bertuccio","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"2026102206401530000_68.3.2600239.135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00692"},{"key":"2026102206401530000_68.3.2600239.136","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2016.09.045","article-title":"Impaired mucus clearance exacerbates allergen-induced type 2 airway inflammation in juvenile mice","volume":"140","author":"Fritzsching","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026102206401530000_68.3.2600239.137","unstructured":"ClinicalTrials.gov . Study to assess the efficacy and safety of itepekimab in adult participants with bronchiectasis (NCT06280391) [clinical trial registry entry]. U.S. National Library of Medicine 2026. https:\/\/clinicaltrials.gov\/study\/NCT06280391"},{"key":"2026102206401530000_68.3.2600239.138","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S2213-2600(24)00225-X","article-title":"Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months","volume":"12","author":"Haworth","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.139","doi-asserted-by":"publisher","DOI":"10.1038\/srep30201"},{"key":"2026102206401530000_68.3.2600239.140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/rccm.202108-1943OC","article-title":"Endotyping chronic obstructive pulmonary disease, bronchiectasis, and the \u201cchronic obstructive pulmonary disease-bronchiectasis association\u201d","volume":"206","author":"Huang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102206401530000_68.3.2600239.141","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41522-020-00160-w","article-title":"Analysis of microbial compositions: a review of normalization and differential abundance analysis","volume":"6","author":"Lin","year":"2020","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2026102206401530000_68.3.2600239.142","doi-asserted-by":"crossref","first-page":"2590841","DOI":"10.1080\/19490976.2025.2590841","article-title":"Impact of data compositionality on the detection of microbiota responses","volume":"17","author":"Hickman","year":"2025","journal-title":"Gut Microbes"},{"key":"2026102206401530000_68.3.2600239.143","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02224"},{"key":"2026102206401530000_68.3.2600239.144","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.01.038"},{"key":"2026102206401530000_68.3.2600239.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.04.016"},{"key":"2026102206401530000_68.3.2600239.146","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026102206401530000_68.3.2600239.147","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00769-2023"},{"key":"2026102206401530000_68.3.2600239.148","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00719-2025"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00239-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:40:30Z","timestamp":1792676430000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00239-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":148,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/13993003.00239-2026"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00239-2026","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}